Independent service organization Serviscope announced this month that it is acquiring $10.5 million in new equity. The infusion should be the last round of private financing before the Wallingford, CT, ISO seeks public funds,according to Emile
Independent service organization Serviscope announced this month that it is acquiring $10.5 million in new equity. The infusion should be the last round of private financing before the Wallingford, CT, ISO seeks public funds,according to Emile Geisenheimer, Serviscope chairman and generalpartner of Nazem & Co., Serviscope's lead investor.
Serviscope has grown dramatically since it was founded in 1990.The company's cash requirements have grown as well, and as a resultServiscope has recently received several rounds of private equityfinancing.
The latest round will ensure the company's long-term stabilityand growth and will support Serviscope as it pursues an aggressiveexpansion strategy, Geisenheimer said. The financing also putsServiscope on a track to go public in the near future.
While Serviscope sorts out its financial picture, the companyis still searching for a new chief executive to replace DonaldSouthard, who left the company earlier this year (SCAN 4/6/94).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.